AZRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Sep 2021 @ 00:00):

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders...

Stats
Today's Volume	629 030
Average Volume	713 030
Market Cap	3.43M
EPS	$-1.600 ( 2021-08-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.845
ATR14	$0.0530 (1.54%)

Insider Trading

Date	Person	Action	Amount	type
2021-09-09	Coelho Mary Theresa	Buy	10 310	Stock option (right to buy)
2021-08-11	Coelho Mary Theresa	Buy	0
2021-07-09	Pennington James	Buy	100 000	Stock option (right to buy)
2021-06-30	Schneiderman Daniel H	Buy	250 000	Stock option (right to buy)
2021-06-30	Schneiderman Daniel H	Buy	35 006	Stock option (right to buy)

INSIDER POWER
0.00
Last 81 transactions
Buy: 5 836 949 \| Sell: 2 173 162

Volume Correlation

Long: -0.02 (neutral)

Short: 0.65 (weak)

Signal:(72.656) Neutral

AzurRx BioPharma Inc Correlation

10 Most Positive Correlations
GAINL	0.969
HILS	0.956
ALR	0.948
MBIN	0.948
PSTX	0.929
WINT	0.928
RELI	0.925
TYRA	0.924
LFMDP	0.922
SATL	0.921

10 Most Negative Correlations
BOCH	-0.962
SHSP	-0.934
TBIO	-0.928
CCSI	-0.927
EYE	-0.925
MMAC	-0.921
ACHC	-0.909
PPYAU	-0.908
SY	-0.902
RCM	-0.897

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AzurRx BioPharma Inc Correlation - Currency/Commodity

0.14
( neutral )

0.08
( neutral )

0.47
( neutral )

-0.07
( neutral )

0.05
( neutral )

AzurRx BioPharma Inc Financials

Annual	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-5 902 903

Q2	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.188

Q1	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.389

Q4	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-11 661 518

Financial Reports:

No articles found.

AzurRx BioPharma Inc

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).